Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

Pancreatic Cancer Early Detection Using a Urine Test for Mutated K-ras DNA

Clinical Trial Details

This clinical trial is for men and women diagnosed with metastatic pancreatic cancer as well as healthy individuals. The purpose of this research study is to develop a safe method for finding pancreatic cancer using a new technology of finding and detecting pancreatic cancer DNA markers in adult urine. In order to continue to improve the way pancreatic cancer is found in patients, the researchers must be able to obtain urine samples from patients who may or may not have pancreatic cancer and test their urine for DNA fragments that contains pancreatic DNA markers. Eligible patients will have urine and blood collected for correlative reference. 

Key Eligibility: 

- Men and women age 18 or older 
- Patient cohort: known diagnosis of pancreatic cancer 
- Control cohort: no known pancreatic cancer 
- Detailed eligibility reviewed when you contact the study team 

Study contact by location

Upper East Side - Manhattan


Carina Puello, RN
(646) 962-3541

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:



Open to Enrollment

Age Group